Format

Send to

Choose Destination
Crit Care Resusc. 2017 Dec;19(4):344-354.

Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX): results of the pilot phase.

Author information

1
Intensive Care Unit, Wellington Regional Hospital, Wellington, New Zealand. Paul.Young@ccdhb.org.nz.
2
Medical Research Institute of New Zealand, Wellington, New Zealand.
3
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
4
Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Australia.
5
Intensive Care Unit, Austin Hospital, Melbourne, Australia.
6
Intensive Care Unit, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
7
Intensive Care Unit, Fiona Stanley Hospital, Perth, Western Australia.
8
Intensive Care Unit, John Hunter Hospital, Newcastle, New South Wales, Australia.

Abstract

OBJECTIVE:

The objective of the intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX) pilot phase, which included the first 100 patients of an overall sample of 1000, was to examine feasibility.

DESIGN:

Investigator-initiated, prospective, parallel-group, pilot randomised controlled trial.

SETTING:

Six medical-surgical intensive care units (ICUs) in Australia and New Zealand, with participants recruited from September 2015 through June 2016.

PARTICIPANTS:

100 patients ≥ 18 years of age who required invasive mechanical ventilation in the ICU and were expected to be receiving it beyond the next calendar day at the time of randomisation.

INTERVENTIONS:

Conservative oxygen therapy or standard care.

MAIN OUTCOME MEASURES:

Eligibility, recruitment rate, and separation in oxygen exposure (fraction of inspired oxygen [FiO2] and oxygen saturation measured by pulse oximetry [SpO2Z]).

RESULTS:

94 of 99 participants (94.9%) were confirmed by study monitors to fulfil the study eligibility criteria. 3.6 patients per site per month were enrolled (95% confidence interval [CI], 2.5-4.7). Patients allocated to conservative oxygen therapy spent significantly more time on an FiO2 of 0.21 in the ICU; median, 31.5 hours (interquartile range [IQR], 7-63.5) for conservative oxygen therapy patients v 0 hours for standard oxygen therapy patients (IQR, 0-10; midpoint difference, 21.5 hours; 95% CI, 9-34; P < 0.0001). Patients allocated to conservative oxygen therapy spent less time in the ICU with an SpO2Z of ≥ 97% than patients allocated to standard oxygen therapy; median, 18.5 hours (IQR, 5-46) for conservative oxygen therapy patients v 32 hours for standard oxygen therapy (IQR, 17-80; midpoint difference, 13.5 hours; 95% CI, 2-25; P = 0.02).

CONCLUSIONS:

Our findings confirm the feasibility of completing the ICU-ROX trial without the need for substantive changes to the study protocol for the remaining 900 trial participants.

TRIAL REGISTRATION:

Australian and New Zealand Clinical Trials Registry (ANZCTRN 12615000957594).

PMID:
29202261
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center